World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
27783
World Ranking
14558
National Ranking
7370

Robert F. Ozols publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert F. Ozols sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 276 publications — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert F. Ozols D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert F. Ozols sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert F. Ozols is affiliated with the Fox Chase Cancer Center in the United States. Their research primarily focuses on medicine with specific attention to subfields including reproductive medicine, cancer research, and surgery.

The main topics in Ozols' work include ovarian cancer diagnosis and treatment, cancer, lipids, and metabolism, as well as intraperitoneal and appendiceal malignancies.

Ozols has contributed to the academic community with publications in notable venues such as the Journal of Clinical Oncology. One prominent paper published in 2023 is titled "Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study."

  • Brian N. Bundy
  • Benjamin E. Greer
  • Jeffrey M. Fowler
  • Daniel L. Clarke-Pearson
  • Robert A. Burger

These frequent coauthors have collaborated with Ozols on research investigations related to cancer treatment protocols.

Within their field of study, Ozols has produced work covering both broad and specialized areas:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Regarding subfields, Ozols' research includes:

  • Reproductive Medicine
  • Cancer Research
  • Surgery

The key scientific topics that define Ozols' research trajectory are:

  • Ovarian cancer diagnosis and treatment
  • Cancer, Lipids, and Metabolism
  • Intraperitoneal and Appendiceal Malignancies

Best Publications

  • Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

    Robert F. Ozols;Brian N. Bundy;Benjamin E. Greer;Jeffrey M. Fowler

  • The anthracycline antineoplastic drugs.

    Robert C. Young;Robert F. Ozols;Charles E. Myers

  • Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Jay W. Carlson

  • Ovarian Cancer: Screening, Treatment, and Follow-up

    Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld

  • Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion

    Thomas C. Hamilton;Margaret A. Winker;Karen G. Louie;Gerald Batist

  • Characterization of a cis-Diamminedichloroplatinum(II)-resistant Human Ovarian Cancer Cell Line and Its Use in Evaluation of Platinum Analogues

    Brent C. Behrens;Brent C. Behrens;Thomas C. Hamilton;Hidetaka Masuda;Karen R. Grotzinger

  • 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

    A du Bois;M Quinn;T Thigpen;J Vermorken

  • Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

    Robert F. Ozols;Robert E. Cunnion;Raymond W. Klecker;Thomas C. Hamilton

  • Reversal of adriamycin resistance by verapamil in human ovarian cancer

    Alfred M. Rogan;Thomas C. Hamilton;Robert C. Young;Raymond W. Klecker

  • Advanced epithelial ovarian cancer: 1998 consensus statements.

    J. S. Berek;K. Bertelsen;A. Du Bois;M. F. Brady

  • Radiation Survival Parameters of Antineoplastic Drug-sensitive and -resistant Human Ovarian Cancer Cell Lines and Their Modification by Buthionine Sulfoximine

    Karen G. Louie;Brent C. Behrens;Timothy J. Kinsella;Thomas C. Hamilton

  • High-Dose Cisplatin in Hypertonic Saline

    Robert F. Ozols;Brian J. Corden;Joan Jacob;Margaret N. Wesley

  • Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

    Corey J. Langer;John C. Leighton;Robert L. Comis;Peter J. O'Dwyer

  • Focus on epithelial ovarian cancer.

    Robert F. Ozols;Michael A. Bookman;Denise C. Connolly;Mary B. Daly

  • Treatment goals in ovarian cancer.

    R. F. Ozols

  • Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.

    Robert F. Ozols;Gershon Y. Locker;James H. Doroshow;Karen R. Grotzinger

  • Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.

    J A Green;D T Vistica;R C Young;T C Hamilton

  • High-dose cisplatin in hypertonic saline in refractory ovarian cancer.

    Robert F. Ozols;Yechiam Ostchega;Charles E. Myers;Robert C. Young

  • RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.

    Seiji Mabuchi;Deborah A. Altomare;Mitchell Cheung;Lili Zhang

  • Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

    Eddie Reed;Robert F. Ozols;Robert Tarone;Stuart H. Yuspa

Frequent Co-Authors

Thomas C. Hamilton
Thomas C. Hamilton Fox Chase Cancer Center
Robert C. Young
Robert C. Young Cornell University
Peter J. O'Dwyer
Peter J. O'Dwyer University of Pennsylvania
Charles E. Myers
Charles E. Myers University of Virginia
Eddie Reed
Eddie Reed National Institutes of Health
Corey J. Langer
Corey J. Langer University of Pennsylvania
Mary B. Daly
Mary B. Daly Fox Chase Cancer Center
Stuart H. Yuspa
Stuart H. Yuspa National Institutes of Health
Miriam C. Poirier
Miriam C. Poirier National Institutes of Health
Maurie Markman
Maurie Markman The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is a broad field, and not all healthcare careers require earning an MD. Many students choose alternative or complementary paths that can be pursued online, offering flexibility for working professionals and career changers.

For those interested in nutrition and wellness, an online BS in Nutrition provides a foundational science background and opens opportunities in health education and counseling. If you’re focused on leadership roles, online MHA programs deliver advanced skills in healthcare administration and management.

Registered nurses seeking to advance may wonder, does RN to BSN require clinicals? Online programs often allow RNs to complete degree requirements with limited or no additional clinical hours, making it more convenient to move forward in your nursing education.

For those aiming for the highest clinical qualifications, the shortest online DNP program options can help working nurses earn a terminal practice degree quickly and efficiently.

Exploring these pathways can help you discover diverse opportunities in the healthcare sector—both inside and outside of traditional medicine.

Best Scientists Citing Robert F. Ozols

Trending Scientists

Recently Published Articles